International Research Journal of Medicine and Surgery (IRJMedS), 2026;3(3):26-31 IRJMedS

Review Article | ISSN (O): 3048-6955 DOI: 10.47857/irjmeds.2026.v03i03.076

Personalized Medicine in Oncology: Current Status and Future Prospects

Mohd Faizan Siddiqui*

International Medical Faculty, Osh State University, Osh City, Kyrgyzstan. *Corresponding Author's Email: Fzn.imf@gmail.com, Faizan@oshsu.kg

Abstract

Personalized medicine, also called precision medicine, is an approach to disease prevention and treatment that accounts for individual variability in genes, environment, and lifestyle. In oncology it has driven a decisive shift away from empirical, one-size-fits-all chemotherapy toward biomarker-directed care in which the molecular profile of a tumour, rather than its anatomical site alone, guides treatment selection. This review summarizes the current status and future prospects of personalized oncology. It outlines the biological rationale rooted in the genomic basis of cancer and the concept of oncogene addiction, and describes the enabling technologies - next-generation sequencing, comprehensive genomic profiling, large reference atlases, and liquid biopsy that have made molecular characterization feasible in routine care. The clinical achievements of targeted therapy are reviewed across haematological and solid tumours, together with the advent of immune checkpoint blockade and the first histology-independent, biomarker-defined drug approvals. Innovations in clinical trial design, including basket and umbrella trials and frameworks for ranking the clinical actionability of molecular alterations, are considered alongside cellular therapies such as chimeric antigen receptor T cells. The review also addresses persistent challenges drug resistance, tumour heterogeneity, the still-modest proportion of patients who benefit, and issues of cost and equitable access before considering future directions in multi-omics, minimal residual disease monitoring, combination strategies, and the integration of artificial intelligence. Realizing the full promise of personalized oncology will require continued biological discovery, pragmatic trial designs, and deliberate attention to accessibility.

Keywords: Biomarkers, Genomic Profiling, Immunotherapy, Personalized Medicine, Precision Oncology, Targeted Therapy.

Introduction

Personalized medicine, widely referred to as precision medicine, is an approach to disease prevention and treatment that takes into account individual variability in genes, environment, and lifestyle for each person. Cancer, one of the leading causes of death worldwide, has become the principal proving ground for this paradigm because of both the burden of the disease and the maturity of the underlying molecular science. The concept gained substantial momentum with the launch of national precision medicine programmes that placed cancer at the centre of their near-term goals, reflecting both the burden of the disease and the maturity of the underlying science (1). Although the idea of tailoring treatment is not new blood typing has guided transfusion for over a century its systematic application to complex diseases has become feasible only recently through advances in molecular biology, genomics, and bioinformatics (2). Several landmark studies established both the feasibility and the clinical value of matching therapy to molecular alterations. Inhibition of the BCR-ABL fusion kinase in chronic myeloid leukaemia and antibody-based blockade of HER2 in breast cancer demonstrated that a single, well-defined driver could be exploited for dramatic and durable benefit (3, 4). Large collaborative sequencing efforts, most notably The Cancer Genome Atlas, subsequently mapped the recurrent alterations across tumour types and exposed both shared and lineage-specific dependencies (5). These achievements, however, also revealed important limitations. The proportion of patients with an immediately actionable and validated target remains modest (6), acquired resistance to targeted agents is almost universal (7), and a randomized evaluation of indiscriminate molecular matching failed to demonstrate a progression-free survival advantage over conventional therapy (8). Together, these findings show that molecular information alone is not sufficient, and that the clinical value of an alteration depends on the strength of the evidence linking it to benefit (9).

(Received 03rd March 2026; Accepted 15th August 2026; Published 25th August 2026)

Despite an expanding catalogue of biomarker–drug pairs and increasingly affordable profiling technologies, the biological rationale, the enabling technologies, the current clinical achievements, and the practical barriers to equitable implementation are most often examined in isolation. A consolidated and up-to-date synthesis that connects the molecular basis of cancer to routine clinical practice, and to the real-world challenges of resistance, cost, access, and reproducibility, is therefore still lacking. This review is intended to help address that gap.

In oncology, this transition from empirical, one-size-fits-all cytotoxic therapy toward biomarker-directed care has been more rapid and more consequential than in any other field of medicine. The central premise of precision oncology is that the molecular characteristics of a tumour, rather than its anatomical site of origin alone, should inform the choice of therapy (10). The overarching aim of this review is to provide an integrated and current appraisal of the status and future trajectory of personalized medicine in oncology. Its novelty lies in bringing together, within a single narrative, the biological foundations, the enabling technologies, the therapeutic achievements across haematological and solid tumours, the innovations in trial design, and the challenges of resistance, heterogeneity, cost, and equity. Accordingly, the review is guided by the following objectives:

(a) to outline the biological rationale that underpins precision oncology;
(b) to describe the technologies that enable molecular characterization of tumours;
(c) to summarize the current clinical achievements of targeted therapy, immunotherapy, and cellular therapy; and
(d) to critically examine the principal limitations and the emerging directions including multi-omics, minimal residual disease monitoring, and artificial intelligence that are likely to shape the field.

Methodology

This narrative review was conducted through a structured search of the peer-reviewed literature. PubMed/MEDLINE, Scopus, and Web of Science were searched for English-language articles using combinations of the terms “personalized medicine,” “precision oncology,” “targeted therapy,” “biomarker,” “immunotherapy,” “next-generation sequencing,” “liquid biopsy,” and “CAR-T.” Landmark clinical trials, seminal conceptual papers, authoritative reviews, and regulatory milestones were prioritized, and the reference lists of retrieved articles were screened to identify further relevant sources. Records were selected on the basis of scientific relevance, methodological quality, and contribution to the conceptual and clinical narrative of precision oncology, with primary emphasis on practice-defining evidence and high-impact peer-reviewed sources. The information extracted was then synthesized thematically into the biological foundations, enabling technologies, clinical applications, and future directions presented below. The overall workflow is summarized in Figure 1.



Figure 1: Schematic Representation of the Review Design, Showing the Sequence from Literature Search and Screening Through Study Selection to Thematic Synthesis

Results and Discussion

Biological Foundations and Enabling Technologies

Cancer is fundamentally a disease of the genome. Malignant cells acquire a defined set of biological capabilities sustaining proliferative signalling, evading growth suppression, resisting cell death, enabling replicative immortality, inducing angiogenesis, activating invasion and metastasis, reprogramming metabolism, and evading immune destruction that together constitute the hallmarks of cancer and provide an organizing framework for therapeutic targeting (11). These capabilities arise from somatic mutations, copy-number changes, and structural rearrangements, a subset of which

act as driver alterations that the tumour depends upon for survival, a phenomenon termed oncogene addiction (12). This dependency is the conceptual basis of targeted therapy: pharmacologically disabling a driver can selec-tively impair the malignant cell while sparing normal tissue. Subsequent refinements of the hallmark framework have incorporated pheno-typic plasticity, non-mutational epigenetic reprogramming, and the contribution of the tumour microenvironment, broadening the range of potentially actionable vulnerabilities (13).

The clinical realization of precision oncology depended on the ability to characterize tumours at the molecular level affordably and at scale. Large collaborative efforts to catalogue the genomic landscape of human cancers established reference maps of recurrent alterations across tumour types and revealed both shared and lineage-specific dependencies (5). In routine practice, next-generation sequencing and comprehensive genomic profiling now allow simultaneous interrogation of hundreds of cancer-associated genes from a single specimen, identifying actionable alterations and informing prognosis and eligibility for targeted agents and clinical trials (14). Minimally invasive liquid biopsy, which detects circulating tumour DNA and other analytes in blood, complements tissue testing by enabling molecular profiling when tissue is inaccessible, by capturing tumour heterogeneity, and by permitting serial monitoring of treatment response and emerging resistance (15).

Targeted Therapy and Immunotherapy

The proof of principle for personalized oncology came from chronic myeloid leukaemia, in which a small-molecule inhibitor of the BCR-ABL fusion kinase transformed a lethal disease into a chronically managed one and demonstrated that targeting a defined molecular driver could yield dramatic, durable responses (3). In solid tumours, antibody-based blockade of the HER2 receptor markedly improved outcomes in the subset of breast cancers with HER2 amplification, coupling a predictive biomarker to a matched therapy (4). The recognition that activating mutations in the epidermal growth factor receptor predict response to receptor tyrosine kinase inhibitors reshaped the management of non-small-cell lung cancer, and analogous biomarker–drug pairs have since been established for numerous alterations, including ALK, ROS1, BRAF, and others (16). The success of synthetic lethality is exemplified by poly (ADP-ribose) polymerase inhibitors, which exploit defective homologous recombination in tumours carrying germline or somatic BRCA mutations (17).

Immune checkpoint blockade, which releases inhibitory constraints on T-cell responses against tumours, has produced durable remissions across a range of malignancies and represents a distinct pillar of personalized oncology (18). Its clinical benefit is enriched in defined molecular contexts. Tumours with deficient mismatch repair and high microsatellite instability, which harbour large numbers of neoantigens, respond to programmed cell death protein 1 blockade regardless of their tissue of origin (19). This observation led to the first histology-independent, biomarker-defined regulatory approvals, in which eligibility is determined by a molecular feature such as microsatellite-instability status or high tumour mutational burden rather than by anatomical diagnosis (20).

Tumour-agnostic Therapy, Trial Innovation and Cellular Therapies

The tumour-agnostic paradigm has been extended to rare oncogenic drivers. Highly selective inhibitors of tropomyosin receptor kinases produced marked and durable responses in adults and children whose tumours carry NTRK gene fusions, irrespective of histology, supporting a second class of site-independent approvals (21). Because many actionable alterations are individually uncommon, conventional trial designs are often impractical, and novel architectures have emerged: basket trials evaluate a single targeted agent across multiple histologies sharing an alteration, while umbrella trials assign patients with one tumour type to different agents according to their molecular profile. To help clinicians prioritize among detected alterations, structured frameworks now rank the strength of evidence linking a molecular target to clinical benefit (9). At the same time, results have been sobering when unselected molecular matching is applied indiscriminately; a randomized comparison of profile-guided therapy versus physician's choice found no progression-free survival advantage, underscoring that not every detected alteration is a validated, actionable target (8).

Adoptive cell therapy represents a further individualization of treatment, in which a patient's own immune cells are genetically engineered to recognize tumour antigens. Chimeric antigen receptor T cells directed against CD19 have achieved high remission rates in relapsed or refractory B-cell malignancies, leading to approvals in acute lymphoblastic leukaemia and lymphoma (22, 23). These therapies are manufactured for the individual patient and illustrate both the potential and the logistical complexity of highly personalized biologics, including the management of characteristic toxicities such as cytokine release syndrome and neurotoxicity (24, 25).

Conclusion

Personalized medicine has reshaped oncology, converting selected cancers from uniformly treated diseases into molecularly defined conditions managed with matched, biomarker-directed therapies. Targeted agents, immune checkpoint blockade, histology-independent approvals, and engineered cellular therapies together demonstrate the clinical value of aligning treatment with tumour biology. Yet the field remains constrained by resistance, heterogeneity, a still-limited pool of validated targets, and inequities in access. Continued progress will depend on deeper biological understanding, pragmatic and adaptive clinical trial designs, integration of multi-omics and computational tools, and a sustained commitment to ensuring that the advances of precision oncology reach all patients who could benefit.

Limitations and Future Prospects

Extending the conclusions above, several limitations continue to temper expectations. When applied across an unselected cancer population, the proportion of patients who benefit from genome-driven therapy at any given time remains modest, reflecting the scarcity of validated targets for many tumours, Acquired resistance is almost universal with targeted agents, driven by secondary mutations, bypass signalling pathways, and the outgrowth of resistant subclones, and intratumoral heterogeneity means that a single biopsy may not capture the full complexity of a tumour. Practical barriers further constrain impact, including the cost of testing and of novel agents, uneven access to molecular diagnostics and clinical trials, disparities across health systems and populations, and the interpretive burden of variants of uncertain significance. Addressing these issues is essential if the benefits of personalized oncology are to be realized equitably rather than concentrated among the few.

Looking ahead, the trajectory of personalized oncology points toward richer and more dynamic characterization of disease. Integrating genomic data with transcriptomic, proteomic, epigenomic, and microenvironmental information promises a more complete picture of tumour biology and its vulnerabilities, and molecular tumour boards are increasingly used to translate this complexity into individualized recommendations. Circulating tumour DNA is moving beyond profiling toward the detection of minimal residual disease and early relapse, with the potential to guide adjuvant treatment and de-escalation. Rational combination strategies aim to forestall resistance, and the incorporation of real-world evidence and adaptive trial designs is accelerating the evaluation of biomarker-matched therapies. Artificial Intelligence and machine learning are emerging as powerful tools for interpreting high-dimensional molecular and imaging data, predicting response, and prioritizing therapeutic options, although their clinical deployment will require rigorous validation, transparency, and attention to data quality and bias.

Abbreviations

ALK: Anaplastic Lymphoma Kinase; BCR-ABL: Breakpoint Cluster Region–Abelson; CAR: Chimeric Antigen Receptor; ctDNA: Circulating Tumour DNA; EGFR: Epidermal Growth Factor Receptor; HER2: Human Epidermal Growth Factor Receptor 2; NGS: Next-Generation Sequencing; NTRK: Neurotrophic Tyrosine Receptor Kinase; PARP: Poly (ADP-ribose) Polymerase; PD-1: Programmed Cell Death Protein 1.

Acknowledgement

None.

Author Contributions

Mohd Faizan Siddiqui: conceptualization, literature review, and manuscript writing. The author read and approved the final version of the manuscript.

Conflict of Interest

The author declares there is no conflict of interest.

Data Availability

Data sharing is not applicable to this article as no new data were created or analyzed in this review.

Declaration of Artificial Intelligence (AI) Assistance

AI-assisted technology was used only for grammar correction and language refinement during preparation of the manuscript. The final content and scientific accuracy were reviewed and approved by the author.

Ethics Approval

Ethical approval was not required, as this is a review of previously published literature and did not involve human participants or animals.

Funding

None.

References

1. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793-95. doi: 10.1056/NEJMp1500523
2. Ashley EA. Towards precision medicine. Nat Rev Genet. 2016;17(9):507-22. doi: 10.1038/nrg.2016.86
3. Druker BJ, Talpaz M, Resta DJ, *et al.* Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031-37. doi: 10.1056/NEJM200104053441401
4. Slamon DJ, Leyland-Jones B, Shak S, *et al.* Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-92. doi: 10.1056/NEJM200103153441101
5. Weinstein JN, Collisson EA, Mills GB, *et al.* The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013;45(1):1113-20. doi: 10.1038/ng.2764
6. Marquart J, Chen EY, Prasad V. Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. JAMA Oncol. 2018;4(8):1093-98. doi: 10.1001/jamaoncol.2018.1660
7. Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15(2):81-94. doi: 10.1038/nrclinonc.2017.166
8. Le Tourneau C, Delord JP, Gonçalves A, *et al.* Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16(13):1324-34. doi: 10.1016/S1470-2045(15)00188-6
9. Mateo J, Chakravarty D, Dienstmann R, *et al*. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2018;29(9):1895-902. doi: 10.1093/annonc/mdy263
10. Garraway LA, Verweij J, Ballman KV. Precision oncology: an overview. J Clin Oncol. 2013; 31(15):1803-05. doi: 10.1200/JCO.2013.49.4799
11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74. doi: 10.1016/j.cell.2011.02.013
12. Vogelstein B, Papadopoulos N, Velculescu VE, *et al*. Cancer genome landscapes. Science. 2013;339(6127):1546-58. doi: 10.1126/science.1235122
13. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31-46. doi: 10.1158/2159-8290.CD-21-1059
14. Chakravarty D, Solit DB. Clinical cancer genomic profiling. Nat Rev Genet. 2021;22(8):483-501. doi: 10.1038/s41576-021-00338-8
15. Wan JCM, Massie C, Garcia-Corbacho J, *et al*. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223-38. doi: 10.1038/nrc.2017.7
16. Mok TS, Wu YL, Thongprasert S, *et al*. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-57. doi: 10.1056/NEJMoa0810699
17. Robson M, Im SA, Senkus E, *et al*. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523-33. doi: 10.1056/NEJMoa1706450
18. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-55. doi: 10.1126/science.aar4060
19. Le DT, Uram JN, Wang H, *et al.* PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509-20. doi: 10.1056/NEJMoa1500596
20. Marabelle A, Le DT, Ascierto PA, *et al*. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1-10. doi: 10.1200/JCO.19.02105
21. Drilon A, Laetsch TW, Kummar S, *et al.* Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731-39. doi: 10.1056/NEJMoa1714448
22. Maude SL, Laetsch TW, Buechner J, *et al.* Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439-48. doi: 10.1056/NEJMoa1709866
23. June CH, O'Connor RS, Kawalekar OU, *et al.* CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361-65. doi: 10.1126/science.aar6711

24. Hyman DM, Taylor BS, Baselga J. Implementing genome-driven oncology. Cell. 2017;168(4):584-99.
doi: 10.1016/j.cell.2016.12.015

25. Bhinder B, Gilvary C, Madhukar NS, *et al*. Artificial intelligence in cancer research and precision medicine. Cancer Discov. 2021;11(4):900-15.
doi: 10.1158/2159-8290.CD-21-0090

How to Cite: Siddiqui MF. Personalized Medicine in Oncology: Current Status and Future Prospects. Int Res J Med Surg. 2026;3(3):26-31. DOI: 10.47857/irjmeds.2026.v03i03.076